Curexo
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Curexo is listed on KOSDAQ and classified under Consumer Discretionary, Retailing. Its market value is US$401.9M. In FY2025 it reported revenue of US$56.3M and operating profit of US$1.8M.
A written company profile is not available yet; the facts above come from exchange and DART data.
Curexo in five facts
Where is Curexo listed and in which sector?
Curexo (Korean name: 큐렉소) trades under KRX code 060280 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Consumer Discretionary sector, Retailing.
How large is Curexo?
Its market capitalisation was US$401.9M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Curexo's latest annual revenue and operating profit?
For fiscal year 2025, Curexo reported revenue of US$56.3M, operating profit of US$1.8M and net income of US$2.1M, per its annual report on DART (data retrieved from DART on 2026-09-05). Revenue was up 34.2% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-05
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Results of extraordinary shareholders' meetingSep 17
- Appointment/dismissal/resignation of an independent directorSep 17
- [Amended] Notice of general shareholders' meetingSep 14
- Investor relations (IR) meetingSep 1
- [Amended] Notice of general shareholders' meetingSep 1
- Notice of general shareholders' meetingSep 1
- Supply contract signed
Curexo disclosed a supply contract with Biorad Medisys Pvt. Ltd., worth US$5.64M, about 11.4% of its recent annual revenue, running through Dec 2026.
Supply contract · May 20 - [Attachment amended] Material event report (convertible bonds)Capital raise · May 20
- Material event report (convertible bonds)
Curexo disclosed convertible bonds to raise US$338K, about 0.1% of its market value.
Capital raise · Apr 22 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
Curexo reported consolidated results for FY2025: revenue of US$51.1M (+34.24% year on year), operating profit of US$1.63M (from a loss a year earlier) and net income of US$1.91M (from a loss a year earlier).
Earnings · Feb 5